Long-Term Treatment for Laron Syndrome with IGF-1 Injection over 22 Years in Saudi Arabia: A Cohort Study
Hormone Research in Paediatrics · 2024
DOI: 10.1159/000543047 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Hormone Research in Paediatrics, 2024. Verfasst von Abdullah Ali Alashwal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Laron Syndrome, Insulin-Like Growth Factor I. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Laron syndrome (LS) is a rare autosomal recessive disorder caused by mutations in the growth hormone (GH) receptor gene, resulting in GH resistance and reduced levels of insulin-like growth factor 1 (IGF-1). Patients with LS exhibit severe growth retardation, low IGF-1 levels, elevated basal GH, and poor response to GH stimulation. Recombinant IGF-1 is the only approved treatment and has been shown to improve linear growth. This study evaluates the long-term efficacy and safety of IGF-1 therapy in a large cohort of LS patients treated at King Faisal Specialist Hospital and Research Center (KFSH & RC), Riyadh, Saudi Arabia over 22 years.
Methods
We conducted a retrospective review of medical records for 28 patients with growth hormone insensitivity syndrome, including 12 males and 16 females, treated with IGF-1 from 1998 to 2020. Patients were selected based on criteria including age over 2 years, height standard deviation score (SDS) ≤−2.8, normal or elevated GH secretion (>2.5 ng/mL), IGF-1 levels
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
- Department of Biostatistics Epidemiology and Scientific computing, King Faisal Specialist Hospital and Research Hospital, Riyadh, Saudi Arabia.
- Department Clinical Genomics, Centre for Genomic Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
- Department of Pediatrics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, amal.bin@hotmail.com.
Zitieren
APA
Alashwal, A. A., Al-Fattani, A., Ramzan, K., Imtiaz, F., & Binladen, A. (2024). Long-Term Treatment for Laron Syndrome with IGF-1 Injection over 22 Years in Saudi Arabia: A Cohort Study. Hormone Research in Paediatrics. https://doi.org/10.1159/000543047
Vancouver
Alashwal AA, Al-Fattani A, Ramzan K, Imtiaz F, Binladen A. Long-Term Treatment for Laron Syndrome with IGF-1 Injection over 22 Years in Saudi Arabia: A Cohort Study. Hormone Research in Paediatrics. 2024. doi:10.1159/000543047
BibTeX
@article{Alashwal2024,
author = {Alashwal, Abdullah Ali and Al-Fattani, Areej and Ramzan, Khushnooda and Imtiaz, Faiqa and Binladen, Amal},
title = {Long-Term Treatment for Laron Syndrome with IGF-1 Injection over 22 Years in Saudi Arabia: A Cohort Study},
journal = {Hormone Research in Paediatrics},
year = {2024},
doi = {10.1159/000543047}
}
EUVIMED